Crowdonomics
WatchlistPortfolio
Novatek Pharmaceuticals, Inc.

Reg CF · Common Stock · Dec 2022

ClosedReg CFCommon Equity
via DealMaker · last checked Sep 29, 2026
Raised
$0 / $5M max
0% of ceiling
Investors
—
—
Estimated pre-money
$30M
—

Financials disclosed in this offering

FY2020–FY2021 · hover for source
$0
$1.1M
FY2020
$0
$3.4M
FY2021
RevenueNet income
Metric
FY2020 audited
FY2021 audited
Income statement
Revenue
$0
$0
Cost of goods sold
$0
$0
Net income
$1,148,011
$3,446,214
Taxes paid
$0
$0
Balance sheet
Cash
$78,288
$16,640
Accounts receivable
$0
$0
Total assets
$78,288
$16,640
Short-term debt
$1,076,299
$2,207,386
Long-term debt
$0
$2,253,479
Total liabilities
$1,076,299
$4,460,865
Other
Headcount
—
5

The fiscal years the issuer disclosed in this offering’s filing, as filed. Full history on the company page.

Deal terms

Est. pre-money$30M
Price / share$2.00
Shares offered25,000

Estimated, not stated: $2.00 × 15,000,000 securities outstanding as of Dec 31, 2021 (Form C filed Dec 21, 2022, p. 57).

Offering details

Target$50,000
Max$5,000,000
Min investment—
OpenedDec 21, 2022
DeadlineDec 14, 2023
ClosedDec 14, 2023
Days active358

Links & provenance

SEC filing
Source: SEC EDGAR
0001952985-22-000002
Last synced Sep 29, 2026

About this data. Raised amounts and investor counts come from the platform listing and may lag or be restated; SEC-reported totals can differ until the next Form 1-Z/C-U. Post-money valuation is computed as pre-money plus amount raised and is shown once the round closes — it is not a traded price. Financial statements are as reported by the issuer. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.